A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.
Financial Summary
| Share Statistics | AIDX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $4.3 | $334.8 | 3% |
|
| Shares Out (Mil) | 7.7 | 41.7 | 17% |
|
| Institutional Ownership | 43.8% | 77.3% | 19% |
|
| Float (Mil) | 8.7 | 34.7 | 18% |
|
| Beta | na | 0.86 | na |
|
| Avg Daily Volume (000s) | 124 | 266 | 38% |
|
| Price Change (52-week) |
na | 60.7% | na |
|
| Growth | AIDX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 46.1% | 11.8% | 95% |
|
| Net Income (5yr) | (19.8%) | (5.8%) | 20% |
|
| EPS (5yr) | (19.6%) | 10.7% | 13 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (18.3%) | (16.1%) | 37% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | AIDX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $2 | $152 | 3% |
|
| Net Income (TTM) (Mil) | ($5) | ($11) | 33% |
|
| EPS (TTM) | ($0.904) | ($0.500) | 22% |
|
| Operating Cash Flow (TTM) (Mil) | ($3) | ($2) | 27% |
|
| Net Cash Flow (TTM) (Mil) | na | $1 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $22 | 14% |
|
| Enterprise Value (Q1) (Mil) | $2 | $304 | 4% |
|
| Valuation | AIDX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.67 | 2.88 | 44% |
|
| P/E | na | 30.5 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.9 | na |
|
| Ratios | AIDX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 27.2% | 59.1% | 31% |
|
| Net Margin | (279.1%) | (7.7%) | 3% |
|
| ROA | (109.7%) | (13.7%) | 5% |
|
| ROE | (256.7%) | (15.9%) | 3% |
|
| Liabilities to Assets | 52.5% | 44.9% | 45% |
|
| F-Score | 4 | 4 | 34% |
|
20/20 Biolabs, Inc. did not pass any screens on 7/30/2026.
